The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Genetically modified animal models. Buy the report here.

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1 therapies, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Genetically modified animal models is a key innovation area in the pharmaceutical industry

A genetically modified animal is one whose genetic material has been altered by adding, changing, or removing certain DNA sequences to introduce a new trait or change a characteristic such as the disease resistance of an animal. These animals have been used as a key tool in functional genomics to generate models for human diseases and to validate new drugs. The methodologies used for transfecting the gene include zinc fingers nucleases (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats (CRISPR).

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 190+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of genetically modified animal models.

Key players in genetically modified animal models – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to genetically modified animal models

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
Regeneron Pharmaceuticals 3739 Unlock company profile
Sanofi 442 Unlock company profile
F. Hoffmann-La Roche 338 Unlock company profile
Biocytogen Pharmaceuticals (Beijing) 205 Unlock company profile
Ligand Pharmaceuticals 120 Unlock company profile
Omeros 117 Unlock company profile
Children's Medical Center 95 Unlock company profile
Jackson ImmunoResearch Laboratories 94 Unlock company profile
Sangamo Therapeutics 78 Unlock company profile
Deerfield Management 78 Unlock company profile
Takeda Pharmaceutical 74 Unlock company profile
Amgen 72 Unlock company profile
AbCellera Biologics 71 Unlock company profile
Bristol-Myers Squibb 66 Unlock company profile
C. H. Boehringer Sohn 66 Unlock company profile
Erasmus MC 63 Unlock company profile
Centre National de la Recherche Scientifique 62 Unlock company profile
Merus 60 Unlock company profile
Kirin Holdings 58 Unlock company profile
Encoded Therapeutics 52 Unlock company profile
E. Merck 51 Unlock company profile
Crescendo Biologics 50 Unlock company profile
Biogen 50 Unlock company profile
AstraZeneca 45 Unlock company profile
Japan Science and Technology Agency 45 Unlock company profile
Helmholtz Association of German Research Centres 40 Unlock company profile
Homology Medicines 37 Unlock company profile
Pfizer 37 Unlock company profile
Massachusetts General Hospital 36 Unlock company profile
Transposagen Biopharmaceuticals 36 Unlock company profile
Bayer 31 Unlock company profile
OncoTherapy Science 31 Unlock company profile
Memorial Sloan Kettering Cancer Center 30 Unlock company profile
ImmunoGen 30 Unlock company profile
TransGenic 28 Unlock company profile
United Therapeutics 28 Unlock company profile
LFB 28 Unlock company profile
APEIRON Biologics 28 Unlock company profile
UK Research and Innovation 27 Unlock company profile
General Hospital 27 Unlock company profile
Eli Lilly and 26 Unlock company profile
St. Jude Children’s Research Hospital 26 Unlock company profile
ITI Scotland 25 Unlock company profile
Genethon 24 Unlock company profile
Riken 24 Unlock company profile
Jackson Laboratory 24 Unlock company profile
Ozgene 22 Unlock company profile
Ministry of Trade and Industry, Singapore 22 Unlock company profile
Ono Pharmaceutical 22 Unlock company profile
Children's Hospital of Philadelphia 22 Unlock company profile

Source: GlobalData Patent Analytics

Regeneron Pharmaceuticals is one of the leading patent filers in the generation of genetically modified animal models. The Regeneron Genetics Center (RGC) is an integrated research initiative that improves patient care by using genomic approaches to expedite drug discovery and development. By using its VelociSuite technology platform, the company enabled the development of one in five of all original, FDA-approved fully human monoclonal antibodies currently on the pharmaceutical market. VelociSuite technologies provides vital services to assist in the drug discovery and development process.

In terms of application diversity, Eli Lilly is the top company, followed by C. H. Boehringer Sohn, and Omeros. By means of geographic reach, Ligand Pharmaceuticals holds the top position, while Ozgene, and C. H. Boehringer Sohn are in the second and third position, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.